Posted On: 12/23/2014 2:40:31 PM
Post# of 30066
Quote:
As a result of MANF being designated as an Orphan Drug, Amarantus is now entitled to certain R&D tax credits equivalent to 50% of the qualified clinical testing expenses for development, a waiver of PDUFA fees, access to government grants and contracts totalling $30 million per year, and seven years of market exclusivity post approval for the target indication.
Not bad...opens an excellent funding door....and that's only from one Orphan indication...
(0)
(0)
